Sarcopenia, a proteomics-derived sarcopenia score, and risk of incident liver outcomes: a prospective cohort study - 18/11/26

Graphical abstract |
Abstract |
Background |
Sarcopenia is associated with adverse outcomes in established liver disease, but its prospective associations with subsequent liver outcomes and the associated circulating proteomic features remain incompletely characterized.
Aims |
To examine the prospective associations of sarcopenia with incident liver outcomes, develop a proteomics-derived sarcopenia score (ProSS), evaluate its predictive value, and explore associated biological pathways.
Methods |
A two-phase analysis was conducted in the UK Biobank. In 492,305 participants, multivariable Cox models assessed the associations of sarcopenia with incident liver outcomes. In a proteomic subcohort of 51,637 participants, ProSS development and internal validation were conducted within a nested five-fold cross-validation framework incorporating multivariable screening, bootstrap-based LASSO, and elastic-net modelling. The incremental prognostic value of ProSS for MASLD and cirrhosis was evaluated using pooled out-of-fold predictions from six Cox models. Functional enrichment and exploratory single-protein indirect-effect analyses were also performed.
Results |
During a median follow-up of approximately 14 years, sarcopenia was associated with higher risks of incident MASLD (HR 1.37, 95% CI 1.26–1.48), cirrhosis (HR 1.58, 95% CI 1.39–1.79), liver cancer (HR 1.86, 95% CI 1.37–2.52), and liver-related mortality (HR 1.91, 95% CI 1.53–2.38). In cross-validation analyses, fold-specific out-of-fold ProSS values were associated with incident MASLD (HR 1.49 per 1-SD increase, 95% CI 1.38–1.61) and cirrhosis (HR 2.39, 95% CI 2.15–2.65). Adding ProSS to a clinical model containing sarcopenia status increased the 10-year AUC from 0.765 to 0.788 for MASLD (ΔAUC 0.023, 95% CI 0.014−0.033; P < 0.001) and from 0.780 to 0.846 for cirrhosis (ΔAUC 0.067, 95% CI 0.043−0.091; P < 0.001). Enrichment analyses highlighted immune and inflammatory signalling, extracellular matrix organization, and cytokine/receptor-related pathways. Exploratory indirect-effect analyses highlighted GDF15, IGFBPL1, and BST2 as the leading protein signals for both MASLD and cirrhosis.
Conclusions |
Sarcopenia was prospectively associated with higher risks of multiple liver outcomes. ProSS provided incremental prognostic information beyond clinical factors and sarcopenia status, particularly for cirrhosis, while the associated circulating proteins may provide biological context for these associations.
Le texte complet de cet article est disponible en PDF.Keywords : Sarcopenia, Proteomics, MASLD, Cirrhosis, UK Biobank
Plan
Vol 31 - N° 2
Article 101029- février 2027 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
